Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma 1

Interventions

pembrolizumab 5Magnetic Resonance Spectroscopy 5Cisplatin 5Carboplatin 5Specimen Handling 4Radiotherapy, Intensity-Modulated 4Platinum 41,2-diaminocyclohexaneplatinum II citrate 4Taxes 2Paclitaxel 2Docetaxel 2peposertib 1ipatasertib 1durvalumab 1dehydroftorafur 1cemiplimab 1atezolizumab 1Zinc Acetate 1X-Rays 1Radiotherapy 1Radiosurgery 1Radiation 1Probiotics 1Observation 1Nutritional Status 1Immunoglobulin G 1Fluorouracil 1Fluorodeoxyglucose F18 1Disulfides 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Laryngeal Neoplasms × peposertib × Clear all
NCT04533750 2026-04-13

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 1 Active not recruiting
21 enrolled
Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡